Pure Global
NCT03880708

China Inherited Ventricular Arrhythmias Registry

China Inherited Ventricular Arrhythmias Registry, a Multicenter, Observational and Prospective Study
China National Center for Cardiovascular Diseases·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ventricular Arrythmia
Study type
Observational
Sponsor & location
Primary sponsor
China National Center for Cardiovascular Diseases
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Oct 24, 2017
End date
Oct 24, 2027
Enrollment
500 participants
Primary outcome

sustained tachycardia/ ventricular fibrillation or sudden cardiac death

Summary

This is an observational, prospective, multi-center registry, aiming at building a risk
 stratification for malignant inherited ventricular arrhythmias, including Brugada
 syndrome(Brs)、Long QT syndrome(LQTS)、Short QT syndrome(SQTS)、Early repolarization
 syndrome(ERS) and Catecholaminergic polymorphic ventricular tachycardia(CPVT). 500
 participants will be recruited from 10 centers in China, with clinical data to be abstracted
 from medical records, and blood samples to be collected for finding related genes and
 promising risk indicators. The follow-up should be made every 6 months.

ICD-10 classifications
Ventricular tachycardiaLeft ventricular failureVentricular septal defectCardiomyopathy, unspecifiedCardiac arrhythmia, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03880708
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03880708 through Pure Global AI's free database. This phase not specified trial is sponsored by China National Center for Cardiovascular Diseases and is currently Recruiting. The study focuses on Ventricular Arrythmia. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.